8-K: Surrozen Announces Positive Clinical Trial Data and Strategic Partnership Milestone

Surrozen reports encouraging Phase 1b trial results for SZN-043, a $10 million milestone payment from Boehringer Ingelheim, and a new research collaboration with TCGFB.

Summary

• Surrozen released its third quarter 2024 financial results and provided a business update, highlighting progress in its clinical programs and strategic partnerships.
• The company's Phase 1b trial of SZN-043 for severe alcohol-associated hepatitis (sAH) showed promising early results, with no drug-related serious adverse events and potential clinical benefits observed in the first cohort.
• Surrozen received a $10 million milestone payment from Boehringer Ingelheim (BI) related to the development of SZN-413 for retinal diseases.
• A new research collaboration with TCGFB was announced, focusing on antibody therapeutics for idiopathic pulmonary fibrosis (IPF), with Surrozen potentially receiving up to $6 million and a warrant for 3,380,000 shares of TCGFB.
• The company nominated a portfolio of novel preclinical ophthalmology product candidates to its R&D pipeline.
• Surrozen's cash and cash equivalents were $31.0 million as of September 30, 2024, but increased to $41 million after the $10 million milestone payment in October.
• Collaboration and license revenue for the third quarter was $10.0 million, compared to zero in the same period of 2023, due to the BI milestone.
• Net loss for the third quarter was $1.4 million, a significant improvement from the $10.4 million loss in the same period of 2023.

Sentiment

Score: 8

Explanation: The document presents a positive outlook with promising clinical trial data, a significant milestone payment, and a new research collaboration. The reduction in net loss is also a positive sign. However, the company's cash burn rate and the inherent risks of drug development temper the overall sentiment.

Positives

• The Phase 1b trial of SZN-043 showed promising early safety and efficacy signals, with no drug-related serious adverse events and potential clinical benefits.
• The $10 million milestone payment from Boehringer Ingelheim strengthens Surrozen's financial position.
• The new research collaboration with TCGFB provides additional revenue potential and a potential equity stake.
• The nomination of new ophthalmology product candidates expands Surrozen's pipeline and potential market opportunities.
• The company's net loss significantly decreased year-over-year, indicating improved financial performance.
• The company has made substantial progress on enrolling patients in the SZN-043 Phase 1b trial.

Negatives

• The company's cash position decreased from $37.8 million to $31.0 million during the quarter, although this was offset by the $10 million milestone payment in October.
• Other expenses increased by $3.1 million due to non-cash changes in the fair value of warrant liabilities.
• Interest income decreased due to a reduction in cash equivalents and marketable securities.

Risks

• The company's future success depends on the successful development and commercialization of its drug candidates, which is subject to significant risks and uncertainties.
• Clinical trials may not yield positive results, and regulatory approvals may not be granted.
• The company may need to raise additional capital to fund its operations and development programs.
• The company is subject to risks related to global economic, political, regulatory, and market conditions.
• The company's collaboration with TCGFB is subject to the risk that the collaboration may not be successful.

Future Outlook

Surrozen anticipates presenting data from the Phase 1b study of SZN-043 at an upcoming liver disease conference and expects proof-of-concept data in the first half of 2025. The company will continue to advance its pipeline and collaborations.

Management Comments

• Craig Parker, President and Chief Executive Officer of Surrozen, stated that the company made substantial progress on enrolling patients in the SZN-043 Phase 1b trial.
• Craig Parker also noted that Boehringer Ingelheim planned to further develop SZN-413 and that Surrozen nominated a portfolio of novel preclinical ophthalmology candidates.
• Craig Parker mentioned that the company is encouraged to see that SZN-043 is safe at the first dose level and showing signs of providing a clinical benefit to patients.
• Craig Parker stated that published data in the severe alcohol-associated hepatitis population indicates an expected mortality rate of approximately 15 to 20% at day 30 and absence of any improvement in markers of liver physiology such as bilirubin.

Industry Context

The announcement highlights Surrozen's progress in the competitive biotechnology sector, particularly in the areas of liver and eye diseases. The collaboration with Boehringer Ingelheim and TCGFB demonstrates the company's ability to attract partnerships and validate its technology. The focus on Wnt signaling is a novel approach in the treatment of degenerative diseases and tissue injuries.

Comparison to Industry Standards

• The reported 15-20% mortality rate at day 30 for severe alcohol-associated hepatitis is consistent with published data, providing a benchmark for evaluating the efficacy of SZN-043.
• The $10 million milestone payment from Boehringer Ingelheim is a significant achievement for a company of Surrozen's size, indicating the potential value of its SZN-413 program.
• The company's focus on Wnt signaling is a novel approach, and there are no direct comparables in terms of specific products, but companies like Regeneron and Genentech are active in the ophthalmology space, and companies like Gilead and Intercept are active in the liver disease space.
• The reduction in net loss from $10.4 million to $1.4 million year-over-year is a positive sign, but the company's cash burn rate remains a concern.

Stakeholder Impact

• Shareholders will likely view the positive clinical trial data and milestone payment favorably.
• Employees may be encouraged by the company's progress and new partnerships.
• Patients with severe alcohol-associated hepatitis and retinal diseases may benefit from the development of new treatments.
• The collaboration with TCGFB may lead to new treatment options for patients with idiopathic pulmonary fibrosis.

Next Steps

• Surrozen will continue to enroll patients in the Phase 1b trial of SZN-043.
• The company expects to present data from the Phase 1b study at an upcoming liver disease conference.
• Surrozen will continue to advance its preclinical ophthalmology product candidates.
• The company will work with TCGFB to discover antibody therapeutics for IPF.
• Boehringer Ingelheim will further develop SZN-413 for clinical testing.

Key Dates

Keywords

SZN-043, SZN-413, Wnt signaling, ophthalmology, liver disease, alcohol-associated hepatitis, retinal disease, Boehringer Ingelheim, TCGFB, clinical trial, biotechnology, antibody therapeutics, milestone payment, research collaboration